1. Home
  2. EPR vs CRSP Comparison

EPR vs CRSP Comparison

Compare EPR & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EPR Properties

EPR

EPR Properties

HOLD

Current Price

$54.97

Market Cap

4.4B

Sector

Real Estate

ML Signal

HOLD

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$60.18

Market Cap

5.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EPR
CRSP
Founded
1997
2013
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.4B
5.1B
IPO Year
1997
2016

Fundamental Metrics

Financial Performance
Metric
EPR
CRSP
Price
$54.97
$60.18
Analyst Decision
Buy
Buy
Analyst Count
11
19
Target Price
$57.06
$71.50
AVG Volume (30 Days)
706.8K
1.7M
Earning Date
02-25-2026
02-10-2026
Dividend Yield
6.45%
N/A
EPS Growth
N/A
N/A
EPS
2.29
N/A
Revenue
$707,150,000.00
$38,337,000.00
Revenue This Year
$5.20
N/A
Revenue Next Year
$2.95
$1,299.68
P/E Ratio
$24.01
N/A
Revenue Growth
3.73
N/A
52 Week Low
$41.75
$30.04
52 Week High
$61.24
$78.48

Technical Indicators

Market Signals
Indicator
EPR
CRSP
Relative Strength Index (RSI) 68.03 60.82
Support Level $54.51 $51.00
Resistance Level $56.03 $57.99
Average True Range (ATR) 1.05 3.01
MACD 0.37 0.25
Stochastic Oscillator 84.21 93.26

Price Performance

Historical Comparison
EPR
CRSP

About EPR EPR Properties

EPR Properties is a real estate investment trust that focuses on underwriting experiential property investments on key industry and property cash flow criteria, and the credit metrics of tenants and customers. The company invests in two property segments: Experiential, including theaters, family entertainment centers, ski resorts, and other attractions; and Education, including early childhood education centers and private school properties. The Company's business is focused on Experiential real estate. The majority of revenue comes from the Experiential sector.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: